Login Register Cart 0
Generic placeholder image

Current HIV Research

Editor-in-Chief

ISSN (Print): 1570-162X
ISSN (Online): 1873-4251

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Design, Synthesis, Docking Studies and Biological Activities Novel 2,3- Diaryl-4-Quinazolinone Derivatives as Anti-HIV-1 Agents

Author(s): Zahra Hajimahdi, Rezvan Zabihollahi, Mohamad Reza Aghasadeghi and Afshin Zarghi*

Volume 17, Issue 3, 2019

Page: [214 - 222] Pages: 9

DOI: 10.2174/1570162X17666190911125359

Price: $65

Abstract

Background: Although major efforts have been devoted to the effective treatment of HIV-1 infection, it has remained one of the leading causes of deaths around the world. So, development of anti-HIV-1 agents featuring novel structure is essential.

Objective: To synthesize novel quinazolinone derivatives and evaluate their anti-HIV-1 activity.

Method: In this study, we designed and synthesized a series of novel 2,3-diaryl-4-quinazolinone derivatives using a one-pot multicomponent reaction. Then, the resulting derivatives were evaluated for anti-HIV-1 activity using Hela cell-based single-cycle replication assay.

Results: Most of the compounds showed efficacy against HIV-1 replication and the compound 9c exhibited the highest activity with EC50 value of 37 μM. Docking studies indicated that synthesized compounds can interact with the key residues of the HIV-1 integrase active site. Binding of the most active compound was consistent with the HIV-1 integrase inhibitors.

Conclusion: Based on our results, these derivatives represent novel lead compounds for the development of new promising anti-HIV-1 agents.

Keywords: Synthesis, molecular docking, design, anti-HIV-1 activity, integrase, 4-quinazolinone.

« Previous
Graphical Abstract

[1]
Zhan P, Pannecouque C, De Clercq E, Liu X. Anti-HIV drug discovery and development: Current innovations and future trends: miniperspective. J Med Chem 2016; 59(7): 2849-78.
[http://dx.doi.org/10.1021/acs.jmedchem.5b00497] [PMID: 26509831]
[2]
Cohen MS, Chen YQ, McCauley M, et al. HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365(6): 493-505.
[http://dx.doi.org/10.1056/NEJMoa1105243] [PMID: 21767103]
[3]
Yeni P. Update on HAART in HIV. J Hepatol 2006; 44(1)(Suppl.): S100-3.
[http://dx.doi.org/10.1016/j.jhep.2005.11.021] [PMID: 16359748]
[4]
Trono D, Van Lint C, Rouzioux C, et al. HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science 2010; 329(5988): 174-80.
[http://dx.doi.org/10.1126/science.1191047] [PMID: 20616270]
[5]
Bon I, Calza L, Musumeci G, et al. Impact of Different Antiretroviral Strategies on Total HIV-DNA Level in Virologically Suppressed HIV-1 Infected Patients. Curr HIV Res 2017; 15(6): 448-55.
[PMID: 29210661]
[6]
Montaner JS, Lima VD, Barrios R, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: A population-based study. Lancet 2010; 376(9740): 532-9.
[http://dx.doi.org/10.1016/S0140-6736(10)60936-1] [PMID: 20638713]
[7]
Craigie R. The molecular biology of HIV integrase. Future Virol 2012; 7(7): 679-86.
[http://dx.doi.org/10.2217/fvl.12.56] [PMID: 23024700]
[8]
Brown PO. Integration of retroviral DNA. Curr Top Microbiol Immunol 1990; 157: 19-48.
[http://dx.doi.org/10.1007/978-3-642-75218-6_2] [PMID: 2203610]
[9]
Zeinalipour-Loizidou E, Nicolaou C, Nicolaides A, Kostrikis LG. HIV-1 integrase: From biology to chemotherapeutics. Curr HIV Res 2007; 5(4): 365-88.
[http://dx.doi.org/10.2174/157016207781023965] [PMID: 17627500]
[10]
Pommier Y, Johnson AA, Marchand C. Integrase inhibitors to treat HIV/AIDS. Nat Rev Drug Discov 2005; 4(3): 236-48.
[http://dx.doi.org/10.1038/nrd1660] [PMID: 15729361]
[11]
Hazuda DJ. HIV integrase as a target for antiretroviral therapy. Curr Opin HIV AIDS 2012; 7(5): 383-9.
[http://dx.doi.org/10.1097/COH.0b013e3283567309] [PMID: 22871634]
[12]
Maertens GN, Hare S, Cherepanov P. The mechanism of retroviral integration from X-ray structures of its key intermediates. Nature 2010; 468(7321): 326-9.
[http://dx.doi.org/10.1038/nature09517] [PMID: 21068843]
[13]
Anthony NJ. HIV-1 integrase: A target for new AIDS chemotherapeutics. Curr Top Med Chem 2004; 4(9): 979-90.
[http://dx.doi.org/10.2174/1568026043388448] [PMID: 15134552]
[14]
Summa V, Petrocchi A, Bonelli F, et al. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J Med Chem 2008; 51(18): 5843-55.
[http://dx.doi.org/10.1021/jm800245z] [PMID: 18763751]
[15]
Evering TH, Markowitz M. Raltegravir (MK-0518): An integrase inhibitor for the treatment of HIV-1. Drugs Today (Barc) 2007; 43(12): 865-77.
[http://dx.doi.org/10.1358/dot.2007.43.12.1146063] [PMID: 18174972]
[16]
Sato M, Motomura T, Aramaki H, et al. Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. J Med Chem 2006; 49(5): 1506-8.
[http://dx.doi.org/10.1021/jm0600139] [PMID: 16509568]
[17]
Shimura K, Kodama E, Sakagami Y, et al. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol 2008; 82(2): 764-74.
[http://dx.doi.org/10.1128/JVI.01534-07] [PMID: 17977962]
[18]
Johns BA, Kawasuji T, Weatherhead JG, et al. Carbamoyl pyridone HIV-1 integrase inhibitors 3. A diastereomeric approach to chiral nonracemic tricyclic ring systems and the discovery of dolutegravir (S/GSK1349572) and (S/GSK1265744). J Med Chem 2013; 56(14): 5901-16.
[http://dx.doi.org/10.1021/jm400645w] [PMID: 23845180]
[19]
Kawasuji T, Johns BA, Yoshida H, et al. Carbamoyl pyridone HIV-1 integrase inhibitors. 2. Bi- and tricyclic derivatives result in superior antiviral and pharmacokinetic profiles. J Med Chem 2013; 56(3): 1124-35.
[http://dx.doi.org/10.1021/jm301550c] [PMID: 23316884]
[20]
Katlama C, Murphy R. Dolutegravir for the treatment of HIV. Expert Opin Investig Drugs 2012; 21(4): 523-30.
[http://dx.doi.org/10.1517/13543784.2012.661713] [PMID: 22380682]
[21]
Narang BK, Grewal GK, Roy S, Bariwal J, Gupta MK, Rawal RK. A novel integrase targeting agent to explore the future prospective of HIV eradication: Dolutegravir. Curr HIV Res 2014; 12(5): 325-38.
[http://dx.doi.org/10.2174/1570162X12666140807150753] [PMID: 25106411]
[22]
Hajimahdi Z, Zarghi A. Progress in HIV-1 integrase inhibitors: A review of their chemical structure diversity. Iran J Pharm Res 2016; 15(4): 595-628.
[PMID: 28243261]
[23]
Zhao XZ, Maddali K, Metifiot M, et al. Bicyclic hydroxy-1H-pyrrolopyridine-trione containing HIV-1 integrase inhibitors. Chem Biol Drug Des 2012; 79(2): 157-65.
[http://dx.doi.org/10.1111/j.1747-0285.2011.01270.x] [PMID: 22107736]
[24]
Telvekar VN, Patel KN. Pharmacophore development and docking studies of the hiv-1 integrase inhibitors derived from N-methylpyrimidones, Dihydroxypyrimidines, and bicyclic pyrimidinones. Chem Biol Drug Des 2011; 78(1): 150-60.
[http://dx.doi.org/10.1111/j.1747-0285.2011.01130.x] [PMID: 21518263]
[25]
Debnath U, Kumar P, Agarwal A, Kesharwani A, Gupta SK, Katti SB. N-hydroxy-substituted 2-aryl acetamide analogs: A novel class of HIV-1 integrase inhibitors. Chem Biol Drug Des 2017; 90(4): 527-34.
[http://dx.doi.org/10.1111/cbdd.12974] [PMID: 28294572]
[26]
Schreier JD, Embrey MW, Raheem IT, et al. Discovery and optimization of 2-pyridinone aminal integrase strand transfer inhibitors for the treatment of HIV. Bioorg Med Chem Lett 2017; 27(9): 2038-46.
[http://dx.doi.org/10.1016/j.bmcl.2017.02.039] [PMID: 28285916]
[27]
Patel SB, Patel BD, Pannecouque C, Bhatt HG. Design, synthesis and anti-HIV activity of novel quinoxaline derivatives. Eur J Med Chem 2016; 117: 230-40.
[http://dx.doi.org/10.1016/j.ejmech.2016.04.019] [PMID: 27105027]
[28]
Rogolino D, Carcelli M, Compari C, et al. Diketoacid chelating ligands as dual inhibitors of HIV-1 integration process. Eur J Med Chem 2014; 78: 425-30.
[http://dx.doi.org/10.1016/j.ejmech.2014.03.070] [PMID: 24704615]
[29]
Billamboz M, Suchaud V, Bailly F, et al. 2-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs) as human immunodeficiency virus type 1 integrase inhibitors: Influence of the alkylcarboxamide substitution of position 4. Eur J Med Chem 2016; 117: 256-68.
[http://dx.doi.org/10.1016/j.ejmech.2016.03.083] [PMID: 27105029]
[30]
Vandurm P, Guiguen A, Cauvin C, et al. Synthesis, biological evaluation and molecular modeling studies of quinolonyl diketo acid derivatives: New structural insight into the HIV-1 integrase inhibition. Eur J Med Chem 2011; 46(5): 1749-56.
[http://dx.doi.org/10.1016/j.ejmech.2011.02.028] [PMID: 21385662]
[31]
Wang Y, Rong J, Zhang B, Hu L, Wang X, Zeng C. Design and synthesis of N-methylpyrimidone derivatives as HIV-1 integrase inhibitors. Bioorg Med Chem 2015; 23(4): 735-41.
[http://dx.doi.org/10.1016/j.bmc.2014.12.059] [PMID: 25618597]
[32]
El-Sharief A, Ammar Y, Zahran M, Ali A, El-Gaby M. Aminoacids in the synthesis of heterocyclic systems: The synthesis of triazinoquinazolinones, triazepinoquinazolinones and triazocinoquinazolinones of potential biological interest. Molecules 2001; 6: 267-78.
[http://dx.doi.org/10.3390/60300267]
[33]
Barker AJ. inventor; Zeneca Ltd., assignee. Quinazoline derivatives and their use as anti-cancer agents. International Patent Classification 6: C07D239/94, A61K31/505, C07D.. 1995 Feb.
[34]
Jatav V, Mishra P, Kashaw S, Stables JP. CNS depressant and anticonvulsant activities of some novel 3-[5-substituted 1,3,4-thiadiazole-2-yl]-2-styryl quinazoline-4(3H)-ones. Eur J Med Chem 2008; 43(9): 1945-54.
[http://dx.doi.org/10.1016/j.ejmech.2007.12.003] [PMID: 18222569]
[35]
Theivendren PS, Palanirajan VK. Quinazoline marketed drugs – A review. Res Pharm 2011; 1: 1-21.
[36]
Wang Z, Wang M, Yao X, et al. Design, synthesis and antiviral activity of novel quinazolinones. Eur J Med Chem 2012; 53: 275-82.
[http://dx.doi.org/10.1016/j.ejmech.2012.04.010] [PMID: 22546200]
[37]
Hajimahdi Z, Zarghi A, Zabihollahi R, Aghasadeghi MR. Synthesis, biological evaluation, and molecular modeling studies of new 1,3,4-oxadiazole- and 1,3,4-thiadiazole-substituted 4-oxo-4H-pyrido [1,2-a]pyrimidines as anti-HIV-1 agents. Med Chem Res 2013; 22: 2467-75.
[http://dx.doi.org/10.1007/s00044-012-0241-5]
[38]
Hajimahdi Z, Ranjbar A, Abolfazl Suratgar A, Zarghi A. QSAR Study on anti-HIV-1 activity of 4-oxo-1,4-dihydroquinoline and 4-oxo-4H-pyrido [1,2-a]pyrimidine derivatives using SW-MLR, artificial neural network and filtering methods. Iran J Pharm Res 2015; 14(Suppl.): 69-75.
[PMID: 26185507]
[39]
Hajimahdi Z, Zabihollahi R, Aghasadeghi MR, Ashtiani SH, Zarghi A. Novel quinolone-3-carboxylic acid derivatives as anti-HIV-1 agents: design, synthesis, and biological activities. Med Chem Res 2016; 25: 1861-76.
[http://dx.doi.org/10.1007/s00044-016-1631-x]
[40]
Faghihi K, Safakish M, Zebardast T, Hajimahdi Z, Zarghi A. Molecular Docking and QSAR Study of 2-Benzoxazolinone, Quinazoline and Diazocoumarin Derivatives as Anti-HIV-1 Agents. Iran J Pharm Res 2019; 18: 1253-63.
[41]
Livani ZA, Safakish M, Hajimahdi Z, Soleymani S, Zabihollahi R, Aghasadeghi MR, et al. Design, synthesis, molecular modeling, in silico ADME studies and anti-HIV-1 assay of new diazocoumarin derivatives Iran J Pharm Res 2018; 17(Special Issue 2): 65-77.
[42]
Safakish M, Hajimahdi Z, Zabihollahi R, Aghasadeghi MR, Vahabpour R, Zarghi A. Design, synthesis, and docking studies of new 2-benzoxazolinone derivatives as anti-HIV-1 agent. Med Chem Res 2017; 26: 2718-26.
[http://dx.doi.org/10.1007/s00044-017-1969-8]
[43]
Parizadeh N, Alipour E, Soleymani S, et al. Synthesis of novel 3-(5-(alkyl/arylthio)-1,3,4-oxadiazol-2-yl)-8-phenylquinolin-4(1H)-one derivatives as anti-HIV agents. Phosphorus Sulfur Silicon Relat Elem 2018; 193: 225-31.
[http://dx.doi.org/10.1080/10426507.2017.1394302]
[44]
Scudiero DA, Shoemaker RH, Paull KD, et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 1988; 48(17): 4827-33.
[PMID: 3409223]
[45]
Lin C-C, Cheng H-Y, Yang C-M, Lin T-C. Antioxidant and antiviral activities of Euphorbia thymifolia L. J Biomed Sci 2002; 9(6 Pt 2): 656-64.
[http://dx.doi.org/10.1159/000067281] [PMID: 12432232]
[46]
HyperChem(TM) Professional 8.0, Hypercube, Inc 1115 NW 4th Street, Gainesville, Florida 32601, USA..
[47]
Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, et al. Automated Docking Using a Lamarckian Genetic Algorithm and and Empirical Binding Free Energy Function. J Comput Chem 1998; 19: 1639-62.
[http://dx.doi.org/10.1002/(SICI)1096-987X(19981115)19:14<1639:AID-JCC10>3.0.CO;2-B]
[48]
Narasimhulu M, Lee YR. Ethylenediamine diacetate-catalyzed three-component reaction for the synthesis of 2,3-dihydroquinazolin-4(1H)-ones and their spirooxindole derivatives. Tetrahedron 2011; 67: 9627-34.
[http://dx.doi.org/10.1016/j.tet.2011.08.018]
[49]
Zarghi A, Zebardast T, Hajighasemali F, Alipoor E, Daraie B, Hedayati M. Design and synthesis of new 1,3-benzdiazinan-4-one derivatives as selective cyclooxygenase (COX-2) inhibitors. Arch Pharm (Weinheim) 2012; 345(4): 257-64.
[http://dx.doi.org/10.1002/ardp.201100138] [PMID: 22076641]
[50]
Zabihollahi R, Sadat SM, Vahabpour R, et al. Development of single-cycle replicable human immunodeficiency virus 1 mutants. Acta Virol 2011; 55(1): 15-22.
[http://dx.doi.org/10.4149/av_2011_01_15] [PMID: 21434701]
[51]
Hajimahdi Z, Zabihollahi R, Aghasadeghi MR, Zarghi A. Design, synthesis and docking studies of new 4-hydroxyquinoline-3-carbohydrazide derivatives as anti-HIV-1 agents. Drug Res (Stuttg) 2013; 63(4): 192-7.
[http://dx.doi.org/10.1055/s-0033-1334964] [PMID: 23487403]
[52]
Zabihollahi R, Vahabpour R, Hartoonian C, et al. Evaluation of the in vitro antiretroviral potential of some Biginelli-type pyrimidines. Acta Virol 2012; 56(1): 11-8.
[http://dx.doi.org/10.4149/av_2012_01_11] [PMID: 22404604]
[53]
Hare S, Maertens GN, Cherepanov P. 3′-processing and strand transfer catalysed by retroviral integrase in crystallo. EMBO J 2012; 31(13): 3020-8.
[http://dx.doi.org/10.1038/emboj.2012.118] [PMID: 22580823]
[54]
Hare S, Gupta SS, Valkov E, Engelman A, Cherepanov P. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 2010; 464(7286): 232-6.
[http://dx.doi.org/10.1038/nature08784] [PMID: 20118915]

Rights & Permissions Print Cite
Article Metrics
22
4
1
1
© 2024 Bentham Science Publishers | Privacy Policy